TITLE:
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)

CONDITION:
Leukemia, Lymphocytic, Chronic

INTERVENTION:
ONTAK

SUMMARY:

      The purpose of this study is to evaluate the safety and effectiveness of ONTAK in previously
      treated patients with chronic lymphocytic leukemia (CLL)
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Patients with B-cell Chronic Lymphocytic Leukemia, Rai Stage 0-II with indication for
             treatment by NCI Working Group Criteria or Rai Stage III or IV.

          -  Patients must have received at least one prior purine analogue-based chemotherapy
             regimen.

          -  ECOG Performance Status of 0, 1, or 2.

          -  Female patients cannot be pregnant and must use birth control during the course of
             the study and for three weeks after the study ends.

        Exclusion Criteria:

          -  Prior treatment with ONTAK (DAB389IL-2) or DAB486IL-2.

          -  Received any therapy for CLL within 35 days prior to study entry.
      
